Sandoz Group AG (Sandoz Group AG) Revenue : $ Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Revenue?

Sandoz Group AG's revenue for the three months ended in Dec. 2023 was $9,979 Mil. Sandoz Group AG does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2023. Sandoz Group AG's Revenue per Share for the three months ended in Dec. 2023 was $23.14. Sandoz Group AG does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023.

During the past 12 months, the average Revenue per Share Growth Rate of Sandoz Group AG was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Sandoz Group AG Revenue Historical Data

The historical data trend for Sandoz Group AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Revenue Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Revenue

9,306.00

9,979.00

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Revenue	9,306.00	9,979.00

Competitive Comparison of Sandoz Group AG's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Revenue distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Revenue falls into.

Sandoz Group AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Sandoz Group AG (OTCPK:SDZNY) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Sandoz Group AG Revenue Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024